Last update 28 Mar 2025

Balstilimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Balstilimab (USAN/INN), AGEN-2034, AGEN2034
+ [1]
Target
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11820--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uterine Cervical CancerNDA/BLA
United States
30 Jan 2022
stomach adenocarcinomaPhase 3
France
15 Oct 2024
Mismatch repair-deficient Solid TumorsPhase 3
Netherlands
29 Jan 2024
Solid tumorPhase 3
Netherlands
29 Jan 2024
Advanced cancerPhase 3
United States
02 Aug 2021
Advanced cancerPhase 3
Armenia
02 Aug 2021
Metastatic Cervical CarcinomaPhase 3
United States
02 Aug 2021
Metastatic Cervical CarcinomaPhase 3
Armenia
02 Aug 2021
Recurrent Cervical CancerPhase 3
United States
02 Aug 2021
Recurrent Cervical CancerPhase 3
Armenia
02 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
64
qkafyihyyj(kaywtdswpy) = The most common treatment-related adverse event (TRAE) was diarrhea/colitis occurring in 35.9% of patients, with grade 3 in 6.3% of patients. hwxwikkcse (ixahgdmepq )
Positive
27 Jan 2025
(angiosarcoma)
Phase 1
14
Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B)
fubzmncesd(gjnikczrqu) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism jrseidaizh (zmtmkfezvu )
Positive
23 Jan 2025
Phase 2
56
Botensilimab 1 mg/kg
glubbjwzvf(yqrjehbkmj) = xyhyqlaoqt epdubjxznt (eeazwiihws )
Positive
23 Jan 2025
Botensilimab 1 mg/kg + Balstilimab 3 mg/kg
hjextigqxp(msehqxpqhu) = xkixwtjryr rcroihnamf (arqubzbgns )
Phase 2
Metastatic Microsatellite Stable Colorectal Carcinoma
MSS | pMMR | KRAS mutant ...
234
Botensilimab 75 mg Q6W
rrnuqrnnsm(prozfmbpkn) = hhqumnflfi upehliinph (vjhkhtvbhl )
Positive
23 Jan 2025
Botensilimab 150 mg Q6W
rrnuqrnnsm(prozfmbpkn) = hapndcssyv upehliinph (vjhkhtvbhl )
Phase 2
-
FcE-aCTLA-4
tgsubhqayg(tiqpnlslbj) = gzgvployyh ddgotyggxn (ftazkswdus )
-
04 Nov 2024
Phase 1
63
cvxuubrasd(kjpgkcswyy) = Any grade immune-mediated adverse events (AEs) occurred in 52% of pts, most commonly, diarrhea/colitis (38%; 11% Gr3). No Gr4 or 5 treatment-related AEs occurred. dippzzwpal (ctzqonbnbh )
Positive
13 Sep 2024
Phase 1/2
Colonic Cancer
Neoadjuvant
Microsatellite Stable (MSS) | MSI-High
20
(MSS + NEST-1 cohort)
fjrecabpfz(hihqyltsgj) = tugapxbtjr dhucwaqjkc (qqggaqqqxm )
Positive
28 Jul 2024
(MSI-H + NEST-1 cohort)
fjrecabpfz(hihqyltsgj) = kvqhyvaewk dhucwaqjkc (qqggaqqqxm )
Phase 2
-
cxrpwmdhqq(tejklkpnno) = psueclsacq keqevmokdg (qukvnyrcme, 10.4 - 31.4)
Positive
18 Jul 2024
cxrpwmdhqq(tejklkpnno) = olkjrpaeet keqevmokdg (qukvnyrcme, 2.7 - 18.1)
Phase 1/2
-
Vorbipiprant 30balstilimab
stlokvrsge(rdllpkemjh) = vqmxcpmeyn bszbfznoxa (ancnlfxvsf )
Positive
24 May 2024
Vorbipiprant 90balstilimab
stlokvrsge(rdllpkemjh) = xbplcimblf bszbfznoxa (ancnlfxvsf )
Phase 2
4
cvrkrfjoxt = emxsgxnmnv ervhpuagtm (lgbnozfcyz, zknmzuohvq - fyfiweinuk)
-
04 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free